The Latest Breaking News from Eli Lilly

Eli Lilly and Co. (NYSE:LLY) stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio. 

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

Data from an earlier study of the drug in patients without diabetes sent company shares tumbling

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral orforglipron in adults with obesity or overweight and type 2 diabetes.

Lilly said it plans to ask regulators to approve the drug by the end of 2025.

People using the jab reported positive results, but many say the increased cost will be prohibitively expensive, and they expect to put the weight back on when they stop

Cost may increase as much as 170% from September, but patients warned against a quick switch to Wegovy

This trend drove WeGovy sales to jump 27 times higher — a 2,660% increase — on Wednesday compared with the typical daily average last month.

Although the market has been uncomfortably choppy in recent sessions, this is also the time for contrarians to pick up hot securities on the cheap.

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam champion turned to a GLP-1 medication.